Astrana Health Beats Q3 2026 Estimates as Revenue Rises 7.1% to $1.024B

Astrana Health (ASTH) beat estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $1.024 billion, up 7.1% from a year earlier, above the $1.020 billion estimate, and adjusted EPS was $0.71, up 7000% from a year earlier, above the $0.46 estimate.

Shares were unchanged in after-hours trading as of 4:04 p.m. ET, to $39.01 from a $39.01 close.

Q3 2026 scorecard

By our calculation, revenue was $3.6 million above the estimate and adjusted EPS was $0.25 above it. The QoQ column compares with the previous quarter's revenue of $972.500 million and adjusted EPS of $0.40. The YoY column compares with $956.048 million and $0.01 in the same quarter a year earlier.

Track record

• EPS record. Adjusted EPS beat the estimate in 3 of the last 8 reports, including this one.
• Revenue record. Revenue beat the estimate in 5 of the last 8 reports.
• Revenue trend. Revenue over the last 5 reports, oldest first: $956.048 million, $950.526 million, $965.100 million, $972.500 million and $1.024 billion.

What to watch

• Next-quarter estimates. Consensus calls for EPS of $0.27 and revenue of $1.02 billion next quarter, based on 3 analysts.
• Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 7.1% increase to $1.024 billion.
• Estimate record. Whether Astrana Health returns to beating EPS estimates, which it did in 3 of its last 8 reports.
• Related coverage. See our reports on Alarm.com, Arlo, SoundHound AI and Affirm.

Sources: Results are from Astrana Health's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Astrana Health's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.